Barclays
BCAB

Barclays’s BIOATLA INC BCAB Stock Holding History

Barclays’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418 Buy
+101
New +$428 ﹤0.01% 5034
2025
Q4 		– Sell
-4
Closed -$126 – 5251
2025
Q3 		$126 Buy
+4
New +$92 ﹤0.01% 5263
2025
Q2 		– Hold
0
– -$2 – 5261
2025
Q1 		– Hold
0
– – – 5210
2024
Q3 		– Sell
-11
Closed -$775 – 5293
2024
Q2 		$775 Sell
11
-613
-98% -$72.9K ﹤0.01% 4696
2024
Q1 		$107K Sell
624
-594
-49% -$73.8K ﹤0.01% 4407
2023
Q4 		$150K Buy
1,218
+1,059
+666% +$91.8K ﹤0.01% 4529
2023
Q3 		$13.5K Sell
159
-18
-10% -$2.29K ﹤0.01% 4252
2023
Q2 		$26.5K Buy
+177
New +$30.4K ﹤0.01% 4076
2023
Q1 		– Sell
-747
Closed -$308K – 5091
2022
Q4 		$308K Buy
747
+709
+1,866% +$294K ﹤0.01% 3611
2022
Q3 		$14K Buy
38
+10
+36% +$3.27K ﹤0.01% 4179
2022
Q2 		$4K Sell
28
-1,306
-98% -$208K ﹤0.01% 4809
2022
Q1 		$333K Buy
+1,334
New +$558K ﹤0.01% 3144

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's BCAB Position: Q2 2026 in Review

Barclays opened a new position in BIOATLA INC (BCAB) in Q2 2026: 101 shares worth $418. The stake represents ﹤0.01% of the portfolio and ranks #5034 among its holdings. This is a return to the name: Barclays previously reported a position in BCAB as recently as Q3 2025.

Barclays first reported a position in BCAB in Q1 2022 and has held it in 11 quarters since. The position peaked at $333K in Q1 2022. 21 funds tracked by Wall St. Rank hold BCAB as of Q2 2026.

  • Barclays held 101 shares of BIOATLA INC worth $418 as of Q2 2026.
  • BIOATLA INC was a new Barclays position in Q2 2026.
  • BIOATLA INC made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5034 holding.
  • Barclays first reported a position in BIOATLA INC in Q1 2022 and has held it in 11 quarters since.
  • Barclays's BIOATLA INC position peaked at $333K in Q1 2022.
  • 21 funds tracked by Wall St. Rank held BIOATLA INC as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.